SAN CLEMENTE, Calif., Aug. 17, 2006 (PRIMEZONE) -- Ocular Therapeutics Incorporated, a wholly owned subsidiary of Advanced Refractive Technologies, (ART) (OTCBB:ARFR), announces that an important early milestone in its development of a treatment for age related macular degeneration (AMD) has been achieved.
